CHIMERIX INC (CMRX) Stock News
NASDAQ:CMRX - Nasdaq - US16934W1062 - Common Stock - Currency: USD
CMRX Latest News, Press Relases and Analysis
Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025?
Not your typical cannabis play. Discover why Jazz Pharma's FDA-approved CBD drug could make it a top cannabis stock to watch in 2025.
Is Chimerix Inc. (CMRX) the Best Performing NASDAQ Stock So Far in 2025?
We recently published a list of 11 Best Performing NASDAQ Stocks So Far in 2025. In this article, we are going to take a look at where Chimerix Inc. (NASDAQ:CMRX) stands against other best performing NASDAQ stocks so far in 2025. On March 29, T. Rowe Price portfolio manager Tony Wang appeared on CNBC’s ‘Closing […]
Is ThredUp Inc. (TDUP) the Best Performing NASDAQ Stock So Far in 2025?
We recently published a list of 11 Best Performing NASDAQ Stocks So Far in 2025. In this article, we are going to take a look at where ThredUp Inc. (NASDAQ:TDUP) stands against other best performing NASDAQ stocks so far in 2025. On March 29, T. Rowe Price portfolio manager Tony Wang appeared on CNBC’s ‘Closing […]
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act...
This MongoDB Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, CMRX, WBA on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VOXX, CMRX, WBA, ML on Behalf of Shareholders
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on March 2, 2025, the Compensation Committee of Chimerix’s...
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, IVAC, BRDG on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Mentions: GLYC
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- -Transaction to add near-term commercial...
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
Mentions: JAZZ
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on February 12, 2025, the Compensation Committee of...
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium
DURHAM, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that...
Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on January 17, 2025, the Compensation Committee of...
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Chimerix to Speak Today at The White House Cancer Moonshot Forum
Chief Scientific Officer, Joshua E. Allen, Ph.D. to Highlight Cancer Moonshot’s Impact on Brain Cancer and Rare Pediatric Disease Drug Development